Children with newly diagnosed immune thrombocytopenia (ITP) treated with eltrombopag as a frontline therapy show improved platelet responses compared to standard care. This research, presented at the American Society of Hematology Annual Meeting, is the first in 30 years to test a new drug for pediatric ITP. Eltrombopag was found to provide sustained hemostatic platelet counts, potentially transforming ITP management for newly diagnosed patients. The study showed significantly higher sustained response rates with eltrombopag, with fewer rescue therapies needed compared to standard care. While some adverse events were reported, there were no thromboembolic events. Future follow-up will assess the durability of responses and potential long-term benefits of this treatment approach.
Source link
New Drug a Game Changer?
